Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;20(3):322-5.
doi: 10.1111/tmi.12430. Epub 2014 Dec 23.

Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru

L Otero  1 , A De Orbegoso, A F Navarro, J Ríos, T Párraga, E Gotuzzo, C Seas, P Van der Stuyft
Affiliations

Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru

L Otero et al. Trop Med Int Health. 2015 Mar.

Abstract

Objective: To determine the time from diagnosis to start of multidrug resistant tuberculosis (MDR TB) treatment in Lima, Peru.

Methods: We studied new smear-positive TB adults that were started on MDR TB treatment or that were switched to it between June 2008 and December 2011.

Results: Time from the first positive smear to MDR-TB treatment was >30 days in 35% (13/37) of patients. Among the 27% (24/88) of patients that switched to MDR-TB treatment, time from the last dose of a drug-susceptible regimen was >30 days.

Conclusion: Start of and switching to MDR TB treatment is still delayed.

Keywords: Peru; Perú; Pérou; Tiempo hasta el inicio del tratamiento; Tuberculosis; multidrug resistant; multirresistente; multirésistante; temps jusqu'au traitement; time to treatment; tuberculose; tuberculosis.

PubMed Disclaimer

References

    1. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. South African Medical Journal. 2012;102:805–807. - PubMed
    1. Davis JL, Dowdy DW, den Boon S, Walter ND, Katamba A, Cattamanchi A. Test and treat: a new standard for smear-positive tuberculosis. Journal of Acquired Immune Deficiency Syndrome. 2012;61:e6–8. - PMC - PubMed
    1. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE. The impact of expanded testing for multidrug resistant tuberculosis using genotype MTBDRplus in South Africa: an observational cohort study. PLoS One. 2012;7:e49898. - PMC - PubMed
    1. Jacobson KR, Theron D, Kendall EA, et al. Implementation of GenoType MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clinical Infectious Diseases. 2013;56:503–508. - PMC - PubMed
    1. Ministerio de Salud. Estrategia Sanitaria Nacional para la Prevención y Control de la Tuberculosis. [accessed 18 June 2013];Informe Operacional 2012. 2010 Available at: www.minsa.gob.pe.

Publication types

Substances

LinkOut - more resources